Therapeutic Modulation of Autophagy in Leukaemia and Lymphoma by Djavaheri-Mergny, Mojgan et al.
cells
Review
Therapeutic Modulation of Autophagy in Leukaemia
and Lymphoma
Mojgan Djavaheri-Mergny 1,2,3,4,5,6,† , Sylvie Giuriato 6,7,8,9,10,11,†, Mario P. Tschan 6,12 and
Magali Humbert 12,*
1 INSERM U1218, Université de Bordeaux, 33076 Bordeaux, France; mojgan.mergny@inserm.fr
2 INSERM U1138, 75006 Paris, France
3 Université Paris Descartes, Sorbonne Paris Cité, 75006 Paris, France
4 Université Pierre et Marie Curie, Sorbonne Université, 75006 Paris, France
5 Cell Biology and Metabolomics Platforms, Gustave Roussy Cancer Campus, 94800 Villejuif, France
6 TRANSAUTOPHAGY: European Network for Multidisciplinary Research and Translation of Autophagy
Knowledge, COST Action CA15138; sylvie.giuriato@inserm.fr (S.G.);
mario.tschan@pathology.unibe.ch (M.P.T.)
7 INSERM, UMR1037 CRCT, F-31000 Toulouse, France
8 Université Toulouse III-Paul Sabatier, UMR1037 CRCT, F-31000 Toulouse, France
9 CNRS, ERL5294 CRCT, F-31000 Toulouse, France
10 Department of Pathology, Boston Children’s Hospital and Harvard Medical School, Boston, MA 02115, USA
11 European Research Initiative on ALK-related malignancies (ERIA), F-31000 Toulouse, France
12 Institute of Pathology, Division of Experimental Pathology, University of Bern, Murtenstrasse 31,
CH-3008 Bern, Switzerland
* Correspondence: magali.humbert@pathology.unibe.ch; Tel.: +41-31-632-8780
† These two authors contributed equally.
Received: 31 December 2018; Accepted: 28 January 2019; Published: 30 January 2019


Abstract: Haematopoiesis is a tightly orchestrated process where a pool of hematopoietic stem
and progenitor cells (HSPCs) with high self-renewal potential can give rise to both lymphoid
and myeloid lineages. The HSPCs pool is reduced with ageing resulting in few HSPC clones
maintaining haematopoiesis thereby reducing blood cell diversity, a phenomenon called clonal
haematopoiesis. Clonal expansion of HSPCs carrying specific genetic mutations leads to increased
risk for haematological malignancies. Therefore, it comes as no surprise that hematopoietic tumours
develop in higher frequency in elderly people. Unfortunately, elderly patients with leukaemia or
lymphoma still have an unsatisfactory prognosis compared to younger ones highlighting the need
to develop more efficient therapies for this group of patients. Growing evidence indicates that
macroautophagy (hereafter referred to as autophagy) is essential for health and longevity. This review
is focusing on the role of autophagy in normal haematopoiesis as well as in leukaemia and lymphoma
development. Attenuated autophagy may support early hematopoietic neoplasia whereas activation
of autophagy in later stages of tumour development and in response to a variety of therapies rather
triggers a pro-tumoral response. Novel insights into the role of autophagy in haematopoiesis will be
discussed in light of designing new autophagy modulating therapies in hematopoietic cancers.
Keywords: macroautophagy; haematopoiesis; leukaemia; lymphomas; therapy response; ageing
1. Introduction
Macroautophagy—Janus-Faced Role in Cancer
Macroautophagy (henceforth autophagy) is a vesicular pathway through which cellular
components are sequestered into a double membrane vesicle called the autophagosome and then
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delivered to lysosomes for degradation (Figure 1) [1]. Autophagy is induced in response to
a variety of intrinsic and environmental stresses including nutrient and energy limiting conditions,
endoplasmic reticulum stress, reactive oxygen species (ROS), hormonal imbalance and exposure to
microorganisms [2]. Depending on the stimulus and context, autophagy can sequester bulk cytoplasmic
components non-selectively or specific cargoes selectively with the help of autophagy-receptors [3].
Under metabolic demands, autophagy induction generates new precursor components, which are used
by cells for energy supply to enable adaptation and cell survival [4]. Autophagy also plays a critical
role in the quality control of intracellular components by promoting the removal and replacement
of cytotoxic damaged organelles and proteins [5]. Such cellular renewal is especially important
in long-lived as well as non-replicative cells such as quiescent and terminally differentiated cells.
There is evidence that autophagy plays an essential role in physiological processes that orchestrate
development, differentiation, cell survival and immune responses. Defective autophagy is linked
to inflammatory and infectious pathologies, cancer, neurodegenerative disorders, liver diseases and
ageing [6].
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Genetic studies of autophagy in yeast have led to the identification of autophagy (Atg)-related
genes whose products drive autophagosome formation through a multistep process [7]. Upstream
of the ATG proteins, several signalling pathways regulate autophagy including the mTOR pathway.
Inhibition of mTOR leads to activation of the ULK1/Fip200 complex, which in turn promotes the
stimulation of the class III PI3K/BECN1 complex. This subsequently leads to the production of PtIns
3P which operates as an initial signal for the formation of a phagophore or initiation membrane.
WIPI proteins are PtIns3P binding effectors that allow the recruitment of several multiprotein
complexes to the autophagosomal membrane including two ubiquitin-like conjugation systems,
ATG5-ATG12-ATG16 and the ATG8 protein family (Microtubule associated protein 1 light chain
(LC3)A, B, C, Gamma-aminobutyric acid receptor-associated protein (GABARAP), GABARAP like
(GABARAPL) 1, GABARAPL2-phosphatidyl ethanolamine (PE) [8]. These steps are instrumental
for the expansion and the closure of the autophagosomal membrane. The last step of autophagy
is the degradation of the sequestered cargoes by lysosomal enzymes generating ATP as well as
a pool of biomolecules. Selective autophagy requires additional proteins known as autophagic
adaptors recruited at the autophagosomal membrane that recognize the cargoes via an LC3-interacting
region (LIR) [1]. Several cellular components can be selectively degraded by autophagy for example
mitochondria (mitophagy), aggregated proteins (aggrephagy) and the endoplasmatic reticulum
(ER-phagy) [9]. Selective autophagy also requires cargo (proteins, mitochondria and pathogens)
ubiquitination. In this scenario, autophagy adaptors recognize ubiquitinated cargoes through their
ubiquitin binding domain. A subset of autophagy adaptors, including SQSMT1/p62, NBR1, Optineurin
and NDP52 operate in selective autophagy through such ubiquitin-dependent mechanisms [10].
Selective autophagy can also occur through an ubiquitin–independent mechanism wherein autophagy
adaptors such NIX and FAM134B bind directly to mitochondria and the endoplasmic reticulum (ER),
respectively [11,12].
Basal macroautophagy is crucial for maintaining cellular homeostasis in resting cells and also for
their proliferation and differentiation [13,14]. In the context of cancer the role of macroautophagy is
complex and clearly depends on tumour stage, type and the driving oncogene. In healthy individuals
autophagy is regarded as a longevity promoting and tumour suppressing process mainly due
to its function to protect cells against genotoxic stress [15]. However, many studies described a
tumour-promoting role for macroautophagy once a tumour has formed as well as during metastasis
by supporting cancer cell survival. Furthermore, therapy-resistance mechanisms may be based on
protective autophagy activated in response to therapy-induced stress [16–20].
In this review, we will summarize the knowledge on autophagy function in healthy hematopoietic
cells and the consequences of its deregulation leading to hematopoietic malignancies. In addition, we
will give an overview on the effect on autophagy-based pre-clinical therapies in hematopoietic cancers
and their potential to improve current therapies. The regulation of autophagy during haematopoiesis
has been recently reviewed in Biochemical Pharmacology [21].
2. Haematopoiesis Development and Autophagy
2.1. Haematopoiesis
Haematopoiesis is a tightly orchestrated physiological process that leads to the generation of
all blood cells from a small population of hematopoietic stem cells (HSCs) [22]. HSCs reside in a
hypoxic stromal niche within the bone marrow in adults where they maintain their quiescent and
self-renewal capacity. HSCs can divide symmetrically, producing two identical daughter HSCs or
asymmetrically producing one HSC and a more proliferative cell primed for differentiation. Through
these hierarchical events, HSCs produce functionally differentiated progenies, namely myeloid
(erythrocytes, megakaryocytes, monocytes, neutrophils, basophils or eosinophils) and lymphoid
(T- and B-lymphocytes) cells [23].
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The self-renewing capability of HSCs allows the lifelong maintenance of an HSC pool. HSCs
may acquire mutations leading to a defect in the replenishment of mature blood cells resulting in
clonal haematopoiesis or hematopoietic diseases. Therefore, HSCs have developed several adaptive
strategies to cope with stressful conditions enabling maintenance of hematopoietic homeostasis [24].
Autophagy is one of the key adaptive mechanisms that occur during haematopoiesis. Here we
summarize some recent discoveries that shed new light on the role of autophagy in normal and
malignant haematopoiesis (Figure 2).
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2.2. Autophagy in HSCs
While HSC rarely cycle and are maintained mainly in a quiescent state (G0 phase of the cell cycle)
under homeostatic conditions, they can produce billions of mature cells needed in adult human and
maintain a pool of HSCs for the entire life of the organism [25,26]. Therefore, HSCs sustain a tight
balance between quiescence and active state. ged SCs show a reduced potential to regenerate the
whole blood system since they are biased towards myelopoiesis [27–30]. Furthermore, old HSCs show
reduced long-term repopulation coupled with reduce chromatin regulation and DNA repair gene
expression while genes involved in inflamm tory response and stre s re ponse are upregulated [31].
Interesti gly, whi e the long-t rm HSCs population decrease with age, the hema opoi tic prog nitor
cells (HSPCs) compartment is increased leading to clonal haematopoiesis.
Several reports te a key role of autophagy in HSCs mainten ce and function.
The conditional deletion of the essenti l autophagy g ne Atg7 in murine HCSs resulted in accumulation
of aberrant mitochondria paralleled by an increase in ROS levels resulting in a drastic increase of DNA
damage. Furthermore, the HSC compartment is reduced whereas myeloid progenitors are increased
in these mice shifting the differentiation balance towards myelopoiesis [32] similarly to an aged HSC
phenotype. Comparable phenotypes were observed when FIP200—a protein of the ULK1/FIP200
complex—was deleted in HSCs, reiterating the role of autophagy in HSCs development [33].
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Interestingly, Atg7 deletion promotes a distinct outcome in HSCs and myeloid cells. In HSCs, Atg7
deletion promotes irreversible impairment of autophagy and causes death. On the other hand, Atg7
deficiency in myeloid cells initiates an alternative compensatory autophagy pathway that enables cell
viability [34]. This suggests that HCS are more vulnerable to autophagy deficiency than differentiated
cells. Indeed, under metabolic stress, long-term HSCs survive by inducing autophagy [34].
Basal levels of autophagy has been shown to control normal HSC differentiation potentially
through a mechanism that involves ROS-mediated degradation of the active form of NOTCH [35,36].
Furthermore, basal level of autophagy is essential for removing activated mitochondria and controlling
the metabolism of young and old HSC which ultimately preserve HSC self-renewal capacity and
regenerative potential [37]. Autophagy was also activated when HSCs were subjected to metabolic
stress. Under this condition, autophagy enables cell survival through a mechanism that relies on
a FOXO-3-driven pro-autophagy gene program [34]. Hence, the fine-tuned regulation of basal and
enhanced levels of autophagy is necessary for proper function and survival of HSCs.
Together, HSCs with impaired autophagy are more prone to ageing leading to increased risk
of developing hematopoietic malignancies. Therefore, further studies on autophagy and aging are
needed to develop novel strategies to prevent premature aging of HSC.
2.3. Autophagy in Development and Differentiation of Lymphocytes
Lymphocytes are comprised of T-, B- and the natural killer cells (NK). T- and B-cells are the major
cellular components of the adaptive immune response [38,39].
2.3.1. T Lymphocytes
T cells develop from self-renewing bone marrow HSC. Upon entering the thymus, multipotent
progenitors develop towards T-cells and loose self-renewal capacity [40]. During thymic differentiation
in mice thymocytes progress from double negative (DN, CD4 CD8) to double positive (DP, CD4+CD8+)
stages. A first critical checkpoint in the thymus takes place at the DN3 stage, marked by the
rearrangement of the TCRβ gene. Following successful rearrangement, the β chain pairs with an
invariant pTα chain to form the pre-TCR that drives cell survival, proliferation and differentiation
through the DN4 to the DP stages. At this point, successful rearrangement of the TCRα gene allows
for the pairing of the α/β chains to produce a functional TCR. Mature single positive T lymphocytes
are then released into the periphery. Thus, the recombinases (Rag1/2) that rearrange TCR genes are
active at the DN3 and DP stages.
Experiments in chimeric mice generated by transplantation of Atg5 or Atg7 knockout foetal
liver cells into lethally irradiated congenic host demonstrated that mice with impaired autophagy
show normal T cell development but cannot fully reconstitute the lymphoid compartment due to a
drastic increase in cell death in the peripheral compartment [41,42]. Furthermore, while expressing
normal TCR levels, Atg5−/− T cells failed to undergo efficient proliferation after TCR stimulation [41]
potentially due to an increase in mitochondria mass [42]. TCR stimulation led to activation of
autophagy [43] that restrained activation of a ligand-initiated signalling cascade by inhibiting the
NF-κB signalling pathway [44].
Autophagy plays a dual role in T cell subsets depending on the stage of differentiation.
Even though autophagy is critical for mature CD4+ T cell death after growth factor withdrawal or in T
cells lacking FADD activity, caspase 8 or Irgm-1 [45,46], it is linked to survival in other subsets. In T
helper 9 cells, autophagy is required for selective degradation of PU-1 which represses differentiation
and anti-tumour activity of these cells [47]. In addition, autophagy has also been shown to be critical
for the survival integrity of regulatory T cells and the maintenance of long-lived memory T cells,
presumably by facilitating the cell adaptation to changing in metabolic demands [48,49]. Moreover,
Zhu et al. showed that TBK-binding protein 1 regulates IL-15-induced autophagy in NKT cells and
this response operates as a regulator of NKT cell development and survival [50].
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Further studies on the role of autophagy in T cell functions at various developmental stages are
still needed to have full comprehension of its role during this process.
2.3.2. B Lymphocytes
B cells undergo differentiation through several stages from pro-B, pre-B and immature B to mature
B-cells. Upon an immune response, B cells are activated and then fully differentiate into plasma cells,
which secrete antibodies against infectious pathogens or for example cancer cells [51].
Reconstitution of irradiated Rag−/− mouse with Atg5−/− foetal liver cells demonstrated a
reduction in peripheral B cells and reduced B cell survival during the final stage of differentiation
within the bone marrow (pro-B to pre-B transition) [52]. Using a conditional Atg5 knockout mouse
model under the control of CD19 or Mb1 promoter, Miller et al. and Arnold et al. demonstrated
that autophagy plays a critical role in humoral immunity through promoting survival of long-lived B
cells and Ab-secreting cells but it is dispensable for pre-B cell transition and B-cell activation under
B-cell receptor stimulation [52,53]. Therefore, complete and partial inhibition of autophagy has distinct
outcomes in B lymphocyte development. Furthermore, autophagy is necessary for the survival of
specific memory B cells but not for the initial generation of memory B cells [54,55]. In addition, WIPI-2
dependent non-canonical autophagy is crucial for B cell activation and mitochondria homeostasis [56].
In line with these data, plasma cells maintenance and antibody response have been shown to be
regulated by an ATG5 dependent autophagy [57].
2.3.3. NK Cells
NK cells are the major component of the innate immune response and serve as a first line of
defence against cells harbouring a variety of perturbations such as malignant transformation or viral
infection. They are part of the recently define innate lymphoid cells family. An NK cell progenitor
specific Atg5 knockout mouse model revealed a crucial role of autophagy in differentiation of these
cells [58,59]. Furthermore, the proper association of FOXO1 and ATG7 on the phagophores is needed
for the appropriate activation and development of functional NK cells in mice [58].
Moreover, NK cells are crucial for tumour immunosurveillance [60]. Thus, a better understanding
of the role of autophagy in this particular lymphocyte subset is crucial for future immunotherapy
targeting cancer cells. Indeed, inhibition of the autophagy gene BECN1 in solid tumours induced a
massive NK cells infiltration leading to tumour growth inhibition [61,62].
2.4. Autophagy in Development and Differentiation of Erythrocytes
During erythropoiesis, cells undergo substantial ultrastructural changes including the removal
of nuclei and other intra-cellular organelles. Therefore, it did not come as a surprise that autophagy
is critical in this process. Earlier studies suggested that autophagy is involved in the elimination
of mitochondria during terminal differentiation of embryonic erythrocytes [63]. Accordingly, the
abundance of autophagy vesicles and multi-vesicular bodies has been observed in K562 erythroid cells
that underwent differentiation upon hemin treatment [64]. This induction of autophagy relies on the
master regulator of haematopoiesis, GATA-1 which has been shown to directly activates gene involved
in autophagy [65].
While inhibiting autophagy in K562 cells by knocking out ATG7 or treatment with Bafilomycin A1
led to a reduction of α-globin and γ-globin, the opposite was found when autophagy was activated in
K562 cells using rapamycin, starvation or in Atg7 knockout mouse model [66]. Earlier studies suggested
that autophagy is involved in the elimination of mitochondria, referred to as mitophagy, during
terminal differentiation of embryonic erythroid cells. NIX (or BNIP3), a BH3-only family member is
upregulated during erythroid differentiation [67]. Interestingly, NIX is required for sequestration of
mitochondria into the autophagosome during terminal erythroid differentiation [68,69] and interacts
directly with GABARAP [70]. Furthermore, during maturation of erythrocytes, autophagosome
maturation is dependent on ATG4 [71].
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The importance of autophagy during erythropoiesis is further highlighted by several autophagy
knockout mouse models. Indeed Atg7−/−, Ulk1−/− and Nix−/− murine erythrocytes are not able to
degrade mitochondria [32,72,73]. Interestingly, only Ulk1−/− erythrocytes have impaired ribosomal
clearance suggesting that several distinct pathways are involved in selective degradation of organelles
by autophagy during maturation of erythrocytes. One mechanism proposed for the regulation of
mitophagy during erythroid differentiation is the requirement of ATG13 to unwanted mitochondria
following binding of ULK1 to Hsp90-Cdc37 chaperone complex [74].
Erythropoiesis is aslo regulated by the neutral sphingomyelinase/ceramide axis. The activation
of this pathway leads to myelopoiesis through a mechanism that involves the inhibition of autophagy
and the modulation of the hematopoietic transcription factors (TFs) GATA-1, GATA-2 and PU.1 [75].
Moreover, NCOA4, a cargo receptor involved in the autophagic turnover of ferritin plays an essential
role during erythroid differentiation as evidenced by defective erythropoiesis in NCO4A K562
knockdown cells and a Ncoa4 zebra fish knockout model [76].
2.5. Autophagy in Development and Differentiation of Macrophages, Neutrophils and Megakaryocytes
During haematopoiesis, HSCs give rise to multi-potent progenitors (MPPs) that subsequently
generate intermediate lineage restricted progenitors. In myeloid differentiation, common myeloid
progenitors (CMP) give rise to granulocyte-macrophage (GM) and megakaryocyte-erythroid (MkE)
progenitors that subsequently develop in differentiated myeloid cells.
2.5.1. Macrophages
Unstimulated monocytes in circulation are short living cells. Stimuli that induce
monocyte-macrophage differentiation induce structural changes and impair the apoptotic program of
monocytes [77,78]. Macrophages are key players in innate immune responses to acute and chronic
inflammation. During monocyte-macrophage transition induced by GM-CSF, an autophagic survival
program is activated [79,80]. Interestingly, M-CSF induced differentiation led to an activation of
autophagy but inhibiting key ATG genes did not affect the survival of these cells. These data were
confirmed in an Atg7 knockout mouse model [79]. While GM-CSF stimulation resulted in activation
of the MAPK8/JNK1 pathway, M-CSF activates a CAMKK2-PRKAA1 pathway [79,80]. Therefore,
further studies are necessary to clarify the interplay between the different kinase cascades, which
lead to autophagy activation during macrophage development. Moreover, inhibition of autophagy
impairs the ability of mature monocytes to phagocyte bacteria suggesting a role for autophagy in
phagocytic function. The activation of autophagy during macrophagic differentiation of monocytes
relies on the activation of CAMKK2-PRKAA1-ULK1 pathway and the purinergic receptor P2RY6 [81].
The role of P2RY6 in autophagy regulation was further supported by data showing that the P2RY6
ligand UDP and the specific P2RY6 agonist MRS2693 can restore normal monocyte differentiation
through reactivation of autophagy in primary myeloid cells of chronic myelomonocytic leukaemia
(CMML) patients. Apart from its role in macrophagic differentiation, autophagy is implicated in the
maintenance of macrophage functions during aging. Indeed, deficiency of autophagy due to the loss of
Atg7 gene causes phenotypes similar to aged macrophages including reduced macrophage functions
(i.e., phagocytosis and nitrite burst) and pro-inflammatory responses [82]. Therefore, autophagy
regulates macrophage homeostasis and function which have potential relevance for the prevention of
inflammatory diseases, which progressively increase with age.
Importantly, autophagy is also influencing the alternative activation of macrophages (M2) [83].
Inhibition of autophagy led to a pro-M2 like polarization while activation of autophagy results
in impaired alternative activation of macrophages. Interestingly, tumour associated macrophages
(TAM) more frequently represent the M2 subtype. Together, deciphering the role of autophagy
during macrophage differentiation and activation will contribute to a better understanding of myeloid
leukaemia development and may provide new strategies to target TAMs in cancer.
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2.5.2. Neutrophils
Neutrophils are the most abundant cell type of the innate immune response. After stimulation,
neutrophils can for example degranulate or release chromatin, nuclear histone protein and serine
proteases to form neutrophil extracellular traps (NETs) [84]. Unbalanced NETs formation has been
linked to autoimmune pathogenesis and inflammatory disorder [85]. The use of 3-Methyladenine
or Ammonium Chloride (NH4CL) as inhibitor of autophagy led to increased NET formation in
neutrophils [86] suggesting that autophagy may play a protective role in NET formation although
these data should be confirmed using more specific autophagy inhibitors. Furthermore, Remijsen Q et
al. showed that both autophagy and superoxide generation are required for NET cell death [87]. In
the same vein, Kajiume et al. recently demonstrated that human neutrophils undergo autophagic cell
death rather than apoptosis [88].
During granulopoiesis, characterized by development from myeloblasts (MB), to promyelocytes
(PM), myelocytes (MC), metamyelocytes (MM), band cells (BC) and finally segmented granulocytes
(PMN) cells acquire specific morphologic features and generate granules [89]. Interestingly, during
these different stages autophagy flux first decreases (MB to MM) to then significantly increase (BC to
PMN) sustaining the metabolic reprogramming during neutrophil differentiation [90].
As macrophages, neutrophils can support tumorigenesis and metastasis formation [91].
For example, exosomes secreted by gastric cancer cells cause activation of autophagy in neutrophils by
activating the NF-κB pathway through HMGB1/TLR4 [92]. Similarly, patients with systemic sclerosis
show increased neutrophil levels with activated autophagy due to the release of platelet-derived
microparticles enriched in HMGB1. Thus, autophagic neutrophils demonstrated an enhanced
mobilization of their granules, proteolytic activity, prolonged survival and NETs formation [87,93–96].
Mouse neutrophils deficient for ATG7 or ATG5 are impaired in degranulation of primary and
secondary granules [97]. Interestingly, while autophagy-deficient neutrophils circulate more and are
more prone towards recruitment to the site of inflammation, they have reduced effector functions. In
line with this observation, it has been shown that neutrophils secrete IL-1β via autophagy mediating
inflammation [98].
Together, the importance of autophagy during neutrophil development and function highlights
its relevance in both immunity and cancer development.
2.5.3. Megakaryocytes
Megakaryocytes (MK) are precursors of platelets that are formed from MK cytoplasm. During
maturation, megakaryocytes undergo endomitosis and therefore become polyploid. Then, they extend
long branches into blood vessels, also known as proplatelets that upon fission become platelets [99].
In Atg7−/− mice megakaryocyte differentiation is impaired due to increased apoptosis and decreased
polyploidy [100].
In mouse models, depletion of Atg7 or Becn1 resulted in lower platelet numbers with increased
size in the peripheral blood [100,101]. In addition, Atg7−/− and Atg7+/− platelets activation and
aggregation were decreased compared to wild type platelets [100]. Accordingly, Becn1+/− mice
demonstrated an increased bleeding time and aggregation [101]. These findings were confirmed in
human cells [101].
3. Autophagy and Lymphoid Tumours
3.1. Aberrant Autophagy in Lymphomas and Lymphoid Leukaemia
3.1.1. Lymphomas
Diffuse large B-cell lymphoma (DLBCL) accounts for 33% of B-Non-Hodgkin Lymphoma and is
the most common subtype. It corresponds to the malignant counterpart of germinal centre (GC) and
post-GC activated cells and is characterized by a diffuse proliferation of large cells harbouring a high
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mitotic rate. This is an aggressive lymphoma, which arises de novo or is the result of the clinical
evolution of less aggressive B-NHL types (like FL and CLL). DLBCL have been subdivided in three
major molecular entities based on gene expression analysis [102]: (a) the germinal centre B-cell like
derived (GCB) DLBCL, (b) the activated B-cell like (ABC) DLBCL which are related to BCR-activated B
cells or B cells committed to plasma cell differentiation and (c) primary mediastinal B cell lymphoma
(PMBCL), which arise from post-GC thymic B cells. GCB and ABC subtypes often occur in older
male adults (median age: 64 years) whereas PMBCL develops in younger adult women. The GCB
subtype is mainly characterized by BCL-2 overexpression, the ABC subtype by NF-κB constitutive
activation and BCL-6 overexpression and the PMBCL subtype by amplification of genes involved
in T cells immunomodulation. The GCB subtype can be cured by chemoimmunotherapy, whereas
more than 50% of the patients presenting the ABC subtype will relapse and die from their malignancy.
Recently, the 2016 World Health Organization classification for lymphomas included a new category
termed high grade B-cell lymphoma with translocations involving MYC and BCL-2 or BCL-6 [103].
Interestingly, BCL-2 inhibits autophagy by direct binding to BECN1. In line with these observations,
patients with a decreased BCL-2 levels have an increase in BECN1 expression that correlates with a
favourable clinical outcome [104,105]. In accordance, Becn1+/- mice demonstrated a higher frequency
of cancer incidence such as lung, liver cancer or B cell lymphoma [106,107]. Another study indicated
that the constitutive repression of autophagy responses in BCL-6-driven DLBCL may contribute to
lymphomagenesis [108]. On the contrary, Li Y. et al. observed a link between Cullin4B (CUL4B)
(a scaffold protein of the CUL4B-RING E3 ubiquitin ligase complex, highly expressed in DLBCL) and
autophagy in the positive regulation of DLBCL progression. They showed that CUL4B regulating
autophagy occurred through JNK signalling and that the inhibition of proliferation induced by CUL4B
deletion may be attributed to the blocking of the pro-survival ability mediated by autophagy [109].
This last study highlights the complexity of autophagy regulation in DLBCL and the necessity to
improve our knowledge on the role of autophagy in lymphoma development.
B-cell Chronic Lymphocytic Leukaemia (B-CLL)/small lymphocytic lymphoma (SLL) is mainly
a disease of older adults (median age: 70 years), characterized by inherent defects in cell death.
This leukaemia/lymphoma progresses slowly and, when patients present clinical symptoms affecting
their quality of life, they are treated by chemoimmunotherapy. El-Khoury et al. demonstrated that
inhibition of autophagy by RNA interference targeting key autophagy genes or by using Chloroquine
or 3-Methyladenine in PBMCs from CLL patients decreased cell viability [110] suggesting that
B-CLL cells are dependent on autophagy. In line, an IκBζ mouse model revealed that IκBζ controls
B-lymphocyte proliferation and triggers a Toll-like receptor (TLR)-dependent antibody response [111].
Interestingly, autophagy is required for TLR9-dependent secretion of IgM in IκBζ positive CLL [112].
In addition, high expression of class 3 PIK3, PIK3R4 and BECN1 are associated with poor outcome in
this disease [113].
DAPK1 is an autophagy-associated gene that is frequently silenced in tumours [114]. Interestingly,
DAPK1 is inactivated in rare CLL cases by mutations leading to increased binding of HOXB7
to the DAPK1 promoter [115]. Gade et al. demonstrated that loss of DAPK1 expression in
CLL is due to a dysfunctional CEBP-β/ATF6 pathway. Furthermore, the inhibition of DAPK1
reduces autophagy and promotes CLL cell growth [116]. This last study points again to
the dual role of autophagy in cancer which was supported by other reports. For instance,
signaling-lymphocytic-activation-molecule-family1 (SLAMF1) expression is associated with favourable
prognosis in CLL cells and is lost in patients with an aggressive form of this disease [117]. Bologna et
al. demonstrated that SLAMF1 activates autophagy activity by indirectly stabilizing the BECN1-VPS34
complex. Accordingly, SLAMF1 negative cells are less sensitive to autophagy-inducing therapy [117].
Mantle cell lymphoma (MCL) is an aggressive disease that constitutes about 5% of B-NHL and rather
occurs in older adults. The majority of the patients are treated by immunochemotherapy. Relapses
are frequently observed and are mainly treated with the proteasome inhibitor, Bortezomib, [118] or
the mTOR inhibitors, Temsirolimus/Everolimus. Indeed, since mantle cell lymphoma overexpress
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cyclin D1, a key protein involved in the G1/S transition phase and regulated by mTOR signalling,
this lymphoma was the first hematologic disease in which the therapeutic efficiency of mTOR
inhibitors was investigated [119]. However, the prognosis of patients is dismal and MCL is still
considered as an incurable disease, in needs for new therapeutics. It is essentially considered as
the malignant counterpart of naïve B cells located in the inner mantle zone of secondary follicles.
This lymphoma is characterized by the overexpression of cyclin D1 due to the t(11;14)(q13;q32)
chromosomal translocation.
MCL patients express high levels of TG2 and NF-κB [120]. Lowering TG2 in MCL cells decreases
proliferation and survival rates. Furthermore, TG2 regulates autophagic flux while inhibiting
autophagy by silencing ATG5 resulted in undetectable TG2 levels. In this context, ATG5 knockout
cells proliferate at a lower rate compared to autophagy-proficient cells.
Phospholipid scramblase 1 (PLSCR1) is a pro-apoptotic gene upregulated upon 9-cis-retinoic
acid and Interferon-a treatment in MCL cell lines [121,122]. Interestingly, PLSCR1 inhibits autophagy
activity reducing MCL cell viability [123].
On the contrary, the hedgehog (hH) pathway in MCL cells promotes the infiltration of cells to
the bone. Inhibiting the hH pathway using LDE225 treatment increased CXCR4 expression levels and
ROS leading to enhanced autophagic activity and cell survival [124].
Burkitt Lymphoma (BL) is an aggressive immature B-cells disease, characterized by MYC gene
rearrangement, positivity for early B cell markers and a high mitotic rate. This is a rare disease in
adults (1–2% of B-NHL), whereas it accounts for 30% of paediatric lymphomas. These patients are
treated by chemoimmunotherapy. Relapsed tumours have dismal prognosis.
Using a mouse model for Burkitt lymphoma, Eµ-Myc transgenic mice, Maclean et al.
demonstrated that disruption of lysosomal function using Chloroquine prevents lymphomagenesis
linking this disease to autophagy [125].
Multiple Myeloma (MM) is a cancer of plasma B cell, invading the bone marrow and characterized
by a high genomic and phenotypic variability [126]. It corresponds to the unrestrained proliferation
of fully differentiated B cells, which excessively produce and secrete monoclonal immunoglobulins.
Treatment options have evolved from chemotherapy [127,128] to targeted therapies, including the use
of proteasome inhibitors [129], immunomodulatory drugs [130] and chaperone protein inhibitors [131].
However, responses are not durable and MM still represents an incurable disease. This disease
primarily occurs in elderly individuals (median age: 69 years). A risk loci for predisposition to
MM is mapped to intron 6 of ATG5 on chromosome 6q21 [132,133]. In addition, high expression
of BECN1 or LC3 is associated with a favourable outcome in MM [134]. These two observations
suggest a disruption of autophagy is critical in MM disease development, while others demonstrate
that autophagy activation is necessary to induce MM survival. Indeed, a recent study described the
role of myeloid-derived suppressor cells (MDSC) in promoting MM cell survival and proliferation
by activating the AMPK pathway. The authors propose that the pro-survival effect of AMPK may be
attributed to the induction of autophagy [135]. Gao D. et al. reported also, in bone marrow cells from
patients with untreated MM, the high expression of the long non-coding RNA MALAT and of HMGB1,
leading to the promotion of autophagy and survival [136].
The anti-apoptotic CHE-1 protein interacts with RNA polymerase II and regulates gene
transcription. Its expression correlates with the progression of MM and is required for cell growth
and survival. Interestingly, CHE-1 is phosphorylated upon cellular stress and binds to the Redd1 and
Deptor promoters where it activates their transcription and consequently attenuates mTORC activity.
CHE-1 expression induces autophagy activity by interfering with both mTORC1 and mTORC2 thereby
linking autophagy to survival and progression of MM [137]. In line with these results, several studies
demonstrated that inhibition of autophagy reduce MM cell survival [138,139]. Surprisingly, other
studies pointed towards a pro-cell death role of autophagy in MM [140,141].
Primary Effusion Lymphoma (PEL) is a very rare B-cell NHL associated with HHV-8/EBV
infections and is mostly observed in human immunodeficiency virus (HIV) positive individuals [142].
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PEL present clinically, in its classic form, as malignant lymphomatous effusions in body cavities
(pleural, peritoneum, pericardium cavities). Extracavitary PEL, characterized by solid mass lesions,
has also been reported [143].
In a recent study, Masud Alam et al. demonstrated that the inhibition of lysosomal degradation
using Chloroquine in PEL cells induced ER stress and subsequent apoptosis, thus suggesting that
autophagy supports cellular survival in PEL [144].
Interestingly, treatment of PEL cells with Epigallocatechin-3-Gallate (EGCG), the major constituent
of green tea, led to suppression of HHV8 replication and ROS production that subsequently induces
autophagy and apoptosis [145]. This last study demonstrates that the role of autophagy in PEL
development needs more clarification.
Anaplastic Large Cell Lymphoma (ALCL), ALK (Anaplastic Lymphoma Kinase) positive account for
1–3% of adult T-NHL but correspond to 15% of childhood lymphoma [146]. This malignancy is
currently treated by chemotherapy (based on anthracyclines) but refractory or relapsed diseases
invariably occur in 30% of the patients, regardless of the drugs and doses used [147]. This lymphoma
is predominantly driven by the NPM-ALK oncogene, encoded by the t(2;5)(p23;q35) [148]. Since
NPM-ALK is a constitutively active tyrosine kinase [149,150], small molecule inhibitors, such as the
first in line Crizotinib [151], have been developed over the past 10 years [152,153]. So far, such targeted
therapies have been hampered by the acquisition of resistance to the drug [154,155]. Recently, new
promising therapeutic modalities have emerged [146,156,157].
The role of autophagy in ALK+ ALCL development has not been studied so far. Using patient
derived cell lines, a single study demonstrated that the inhibition of autophagy by either siRNA
directed to ATG7 or Chloroquine alone did not significantly affect cell viability [158].
Follicular Lymphoma (FL) represents about 20% of B-NHL, placing it as the second most common
lymphoma. It arises in older adults (median age: 60 years) and corresponds to the malignant
counterpart of normal germinal centre B cells. Tumour cells commonly invade the bone marrow and are
characterized (in 85% of the cases) by the overexpression of the anti-apoptotic protein BCL-2, as a result
of the t(14;18)(q32;q12) chromosomal translocation. Other mutations, notably in different epigenetic
modifiers such as the mixed-lineage leukaemia 2 (MLL2) protein (a histone H3 methylase), have
been linked to the development of FL as well. This disease is the most frequent indolent lymphoma.
However, it can evolve to DLBCL (in 20–30% of the cases) over time and it largely remains an incurable
disease. The treatment of patients has greatly improved since the use of anti-CD20 monoclonal
antibody-based therapy (called Rituximab (RTX)) [159], in combination with chemotherapy [160]
or as a single therapeutic agent [161]. Recently, the immunological microenvironment has been
proposed as an indicator of prognosis [162,163]. Those last years, new therapeutic options have
emerged including immunomodulatory drugs, newer monoclonal antibodies, BH3-mimetics and
kinase inhibitors. Regarding the autophagy regulation in B-cells, Mc Carthy et al. found that FL
samples showed significantly decreased levels of both SQSMT1/p62 and LC3 compared with reactive
B-cells, indicative of an increased autophagy activity in FL. This dysregulation of autophagy in human
follicular lymphoma was found independent of overexpression of BCL-2 [164]. Interestingly, FL which
express high LC3A levels also harboured a high HIF-1α expression, suggesting a link between hypoxia
and activation of autophagy in FL [165]. To our knowledge, no study on the role of autophagy in the
disease development or sustainment has yet been performed.
3.1.2. Acute Lymphoid Leukaemia
Acute Lymphoid Leukaemias (ALL) account for 20% of acute leukaemia in adults and is the
most common haematological malignancy in children. It is a heterogeneous disease harbouring
different genomic abnormalities such as chromosome number or structure abnormalities, DNA
copy number alterations and mutations. 80% of ALL arise from B cell precursors mainly (B-ALL)
and 20% from thymocytes (T-ALL). Treatments classically involve chemotherapy (glucocorticoid,
Vincristine and an anthracycline) but recent advances in genome profiling not only led to a better
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stratification of the disease but also to the development of new efficient targeted therapy for some
specific subtypes [166–171]. As a consequence, the clinical outcome, notably of children with ALL, has
considerably improved over the last years, with a cure observed in 80% of the cases. Concerning ALL
in adults, only 25 to 50% of patients achieve long-term remission. Thus, new therapeutics are still
needed to improve the outcome of patients.
Interestingly, a BECN1 splice variant was identified in the ALL cell line 697 with a deletion of
exon 11. BECN1 Del-E11 demonstrated a reduction in autophagy induction [172]. Of note, 697 cells
treated with Bafilomycin A1 have a reduction in engraftment in NOD/SCID mice. On the contrary,
in a paediatric t(1;19) pre-B acute lymphoblastic leukaemia (pre-B ALL) cell line model, induction of
autophagy by either starvation or rapamycin leads to the degradation of DNA pold1 and RNA pol
potentially inhibiting cell growth [173]. In line with these observations, the use of Torin-2 on pre-B ALL
cells inhibited mTOR activity and increased autophagy paralleled by inhibition of cell growth and cell
viability [174], pointing toward a tumour suppressor role of autophagy. Clearly, the role of autophagy
in lymphoid malignancies is still debated and might be subtype specific. Therefore, further studies are
needed to better understand the role of this recycling mechanism in lympho- and leukemogenesis.
3.2. Autophagy-Based Treatment Strategies in Lymphomas and Lymphoid Leukaemia
3.2.1. Lymphomas
Diffuse large B-cell lymphoma (DLBCL): Several studies related to the role of autophagy in DLBCL
treatment have been recently published. In 2012, Jia et al. demonstrated that Bortezomib treatment of
DLBCL promoted autophagy, which, through the degradation of IkBa, contributed to NF-κB sustained
signalling and drug resistance [175]. They conclude that blocking both autophagy and proteasome
pathways could have a great potential in killing DLBCL cells. Another group reasoned that since
the phosphatidyl-inositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signalling
pathway is often constitutively activated in DLBCL, treatment with the pan-class I PI3K inhibitor
NVP-BKM120 could be beneficial in patients. Using different DLBCL cell lines, the authors showed
that this compound decreased cell proliferation and induced apoptosis together with cytoprotective
autophagy. Indeed, they further demonstrated that combining autophagy pharmacological inhibition
(by using Chloroquine, 3-Methyladenine or Bafilomycin A1) with NVP-BKM120 further decreased
DLBCL viability [176]. Yuan et al. demonstrated also that Tenovin-6 inhibited cell proliferation and
survival of DLBCL by blocking autophagy [177]. SM1044, a newly synthetized antimalarial artemisinin
derivative, demonstrated a significant anti-tumour effect on DLBCL cell lines. SM1044 induces
autophagy that promotes Survivin degradation followed by apoptotic cell death [178]. Autophagy
inhibitors abrogate SM1044-induced cell death. High expression of Survivin is associated with poor
prognosis and can be overcome by inducing a selective degradation of Survivin by autophagy.
Li et al. found that the inhibition of the long non-coding RNA MALAT-1, in several DLBCL cell
lines, resulted in autophagy activation and to a higher sensitivity to chemotherapy [179].
B-cell Chronic Lymphocytic Leukaemia (B-CLL)/Small Lymphocytic Lymphoma (SLL): Han et al. showed
in 2008 that B-CLL cells resistance to TRAIL (TNF-related, apoptosis-inducing ligand) involved the
induction of cytoprotective autophagy and that the inhibition of autophagy genes (Becn-1 and Atg5)
sensitized the leukemic cells to the drug [180]. Along the same lines, Amrein et al. reported in 2011 that
B-CLL cells treatment with Dasatinib, a tyrosine kinase inhibitor, induced cytoprotective autophagy
(in a p53-dependent pathway) and drug resistance [181]. Finally, in 2012, Kovaleva et al. demonstrated
that, independently to any drug treatment, miR-130a mediated autophagy inhibition (at early step in
the autophagy process, through Atg2B and Dicer1 gene expression downregulation) drives B-CLL cells
to cell death, thus pointing out the constitutive pro-survival role of autophagy in this disease [182].
Interestingly, the nucleoside analogue, 8-Chloro-adenosine that is in phase I-II clinical trial induces
in vitro and in vivo autophagy in CLL [183]. Unfortunately, in the latter study, the authors did not
investigate the impact of autophagy modulation on treatment response.
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A selective HDAC1, 2, 3 and 11 inhibitor, MGCD0103, triggers cell death in primary CLL cells by
inhibiting autophagy [110,184]. Indeed combination treatment of Flavopiridol that induces protective
autophagy, with MGCD0103 improves the efficacy of the treatment. Accordingly, in primary CLL cells,
Tenovin-6, a Sirtuin targeting small molecule, induces cell death by inhibiting late stage of autophagy,
thus preventing its protective effect [185,186].
Recently, in a study aimed to understand the role of the bone marrow microenvironment in CLL
resistant cells to Vorinostat treatment, Ding et al. found that autophagy in stroma cells fuels CLL cell
growth and that its inhibition remarkably decreases stromal protection and overcomes the resistance
to Vorinostat in CLL [187].
Mantle cell lymphoma (MCL): The cell survival-promoting role of autophagy in MCL has been
reported in many studies. Zhang et al. found that under stress, the TG2 (transglutaminase 2)- NF-κB
-IL6 signalling pathway triggered autophagy to promote cell survival, lymphoma progression and
drug resistance [120]. The same group also demonstrated that the CXCR4/SDF-1 signalling pathway
led to autophagy activation, acting as a survival mechanism upon MCL dissemination in the bone
marrow [188]. Another study by Mastorci et al. has shown that the 9-cis-retinoic acid (RA)/Interferon
(IFN)-α combination increased phospholipid scramblase 1 (PLSCR1) expression and led to the
inhibition of cytoprotective autophagy through direct interaction and blockade of the ATG12/ATG5
complex. As a consequence, the authors also demonstrated that the combination of RA/IFN-α
with chemotherapy or proteasome inhibitor enhanced apoptosis [123]. Another drug, Flavopiridol,
a cyclin-dependent kinase inhibitor (CDKI), was also shown to be effective in MCL cells. However,
cytoprotective autophagy restrained its tumour suppressing effect. The combination of 17-AAG
(Hsp90 inhibitor) with Flavopiridol enhanced tumour cell apoptosis through BECN-1 degradation,
ERK inactivation and autophagy suppression [189]. Finally, autophagy mediated degradation of
CD74 was shown to restrain the efficiency of anti-CD74 monoclonal antibody Milatuzumab and to
protect MCL cells from such immunotherapy [190,191]. Alinari et al. described how the synthetic
sphingosine analogue, FTY720, potentiated the Milatuzumab onco-immunosuppressive effects in MCL
by blocking the autophagy-lysosome dependent degradation of CD74 [190]. Altogether, these studies
clearly highlight the cytoprotective role of autophagy in MCL, thus opening up a new therapeutic
strategy, based on autophagy inhibition, to improve MCL patient’s outcome.
Bortezomib induces NOXA stabilization in MCL cells. Interestingly, inhibition of autophagy by
either 3-Methyladenine or Orlistat potentiates NOXA stabilization induced by UPR-inhibition leading
to a significant cell death increase [192]. Accordingly, RAD001 induces apoptosis in the majority of
MCL cells with low cytotoxic effect on normal T and B cells [193]. Interestingly, RAD001 MCL resistant
cells have high autophagic activity compared to responding cells that is linked to their ability to escape
the treatment. The resistance can be overcome by the use of Chloroquine.
In a subset of haematological cell lines, including myeloid leukaemia, lymphoid leukaemia, T cell
lymphoma and mantle cell lymphoma, Nahimana et al. first demonstrated in 2009 that the treatment
of the different cell lines with APO866 (an inhibitor of nicotinamide phosphoribosyltransferase
(NAMPT), a key enzyme in nicotinamide adenine dinucleotide (NAD) biosynthesis) promotes cell
death associated to autophagy induction [194]. A few years later, the same group further confirmed in
a broad panel of haematological cancer cell lines (including T-acute lymphoblastic leukaemia (T-ALL),
Burkitt lymphoma (BL), acute myeloid leukaemia (AML), multiple myeloma (MM)) and primary
cells isolated from patients with AML and B-CLL that autophagy was indeed essential for APO866
cytotoxic effects [195]. Mechanistically and chronologically, autophagy was found to be activated first
(as evidenced by LC3 turnover assay, puncta formation and SQSMT1/p62 degradation) and responsible
for the degradation of CAT/catalase, a main cellular antioxidant, thus resulting in an increase in ROS
levels, delayed caspases activation and subsequent cell death. Indeed, autophagy inhibition (especially
through shRNA targeting ATG5, ATG7 but not through shRNA targeting BECN1) or CAT exogenous
addition, blocked APO866-killing effects. Thus, this study places non-canonical autophagy as a critical
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first cellular answer to APO866, that is necessary to drive different haematological cancer cell lines to
apoptotic cell death.
Burkitt Lymphoma (BL): In a model of MYC-induced lymphoma, Amaravadi et al. have shown
in 2007 that combining alkylating chemotherapy with autophagy inhibition (using Chloroquine or
shRNA targeting ATG5) enhanced cell death and tumour regression [196]. More recently, other
demonstrations for a cytoprotective role of autophagy in BL have been brought by the work of Hart
et al., linking accumulation of unfolded proteins in the endoplasmic reticulum (ER) and subsequent
higher level of unfolded protein response (UPR) to cytoprotective autophagy activation and tumour
cell survival [197]. Another study by Ni et al. demonstrated that treatment of BL cells with Gossypol
(a natural BCL-2 inhibitor) induced reactive oxygen species (ROS) production and translocation
of high mobility group box 1 (HMGB1) from the nucleus to the cytoplasm, which resulted in the
activation of protective autophagy [198]. Finally, Zeng et al. reported in 2013 that recombinant
human arginase (rhArg) treatment in Daudi and Raji cells induced proliferation arrest, apoptosis
and cytoprotective autophagy. They further demonstrated that combining rhArg treatment with
pharmacological or molecular autophagy inhibitors resulted in increased PARP cleavage and higher
percentage of apoptotic cells [199]. Recently, Métayer et al. and Fan et al. reported the cytoprotective
function of autophagy in asparaginase-treated (and not arginase-treated) Burkitt lymphoma cells [200]
and in Vismodegib (an inhibitor of Hedgehog signalling pathway)-treated BL cells [201], respectively.
Pujals et al. reported also that the resistance to Nutlin-3 (a p53 pathway activator) induced apoptosis,
in EBV-positive BL with a latency III phenotype, involved the activation of autophagy and could be
overcome by addition of Chloroquine [202].
Fan J. et al. reported in 2013 that treatment with a chimeric anti-human HLA-DR monoclonal
antibody (chLym-1) induced autophagy (as evidenced by LC3 turnover assay, puncta formation and
SQSMT1/p62 degradation) and that it constituted as a prerequisite to drive cells towards cell death.
Indeed, the pharmacological (3-Methyladenine, Ammonium Chloride) or molecular (siRNA targeting
Atg5) inhibition of autophagy suppressed the cytotoxic effects (growth inhibition, caspase-dependent
apoptosis, antibody dependent cell death (ADCC) and complement-dependent cytotoxicity (CDC))
of chLym-1. Therefore, this study highlighted the potential benefit of chLym-1 combination with
autophagy inducers in B-NHL cells [203].
Granato et al. reported that the treatment of BL cells by Quercetin (a bioflavonoid) resulted in
PI3K/Akt/mTOR signalling inhibition and autophagy induction, which contributed to mutant c-Myc
reduction. Thus, by stimulating the degradative function of autophagy, Quercetin induced a strong
cytotoxic effect against Burkitt’s lymphoma [204].
Li et al. reported recently that autophagy cell death occurred upon arsenic trioxide (As2O3)
treatment. The 3-Methyladenine compound was found to reverse BECN1 and BCL-2 expression up-
and down-regulation, respectively, which resulted in an increase in cell viability through inhibition
of autophagy cell death and apoptosis [205]. In another study, Dong et al. have reported in 2013
that the combination of the histone deacetylase inhibitor valproic acid (VPA) with mTOR inhibitor
(Temsirolimus) synergistically inhibited BL cell growth in a murine xenografted model, through the
activation of autophagic cell death [206]. Along the same line, a recent work by Ono et al. reported the
potent action of rapamycin in inducing autophagic cell death in murine subcutaneously xenografted
BL cells. Of note, they highlighted the successful specific delivery of liposome-encapsulated rapamycin,
through their conjugation with anti-CD19 antibodies [207]. Finally, Turzanski et al. described the
occurrence of autophagic cell death in BL cells owing to rituximab treatment [208].
Multiple Myeloma (MM): Recently, the role of autophagy in MM development and drugs resistance
was investigated (for a review: [209]). The initial work of Hoang et al. demonstrated that autophagy
blockade (using Chloroquine or 3-Methyladenine treatment) resulted in MM cells death, thus
suggesting the pro-survival role of autophagy under basal conditions [138].
A study of Pan et al. in 2011 demonstrated the cytoprotective role of autophagy following
DNA-damaging chemotherapy [210]. Indeed, the authors found that Melphalan and Doxorubicin
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induced autophagy in different MM cell lines, as evidenced by autophagosome accumulation upon
electron microscopy quantification and LC3 turnover assay. Furthermore, autophagy inhibition,
through the use of pharmacological inhibitors (3-Methyladenine, Hydroxychloroquine) or shRNA
targeting BECN1 or ATG5 resulted in a significant improvement of the anti-myeloma activity of the
chemotherapeutic treatment, both in vitro (increased apoptosis cell death) and in vivo (xenografted
tumour growth prevention through apoptosis induction). Along the same line, HMGB1 knockdown in
MM cells or in mice led to autophagy inhibition, which was associated with the potentiation of the
dexamethasone chemotherapeutic effects, that is, increased apoptosis in vitro and reduced tumour
burden in vivo [211].
Another study by Chen et al. in 2014 reported a cytoprotective function of autophagy in MM
cells submitted to Bortezomib treatment [212]. In this setting, the authors further demonstrated that
the combination of HDAC inhibitors and BH3-mimetics (ABT-737) resulted in an increase in BIM
protein levels, which in turn, directly interacted with BECN1 and blocked the induction of autophagy.
Thus, the authors conclude that targeting BIM in MM cells, by disabling cytoprotective autophagy,
could overcome acquired Bortezomib resistance [212]. Other studies demonstrated the cytoprotective
role of autophagy. The HDAC6 genetic knockout or the use of the HDAC6 inhibitor C1A in MM
cells were found to induce cell death by blocking the autophagy degradation pathway of malformed
proteins [213]. Similarly, Tigecycline (a glycylcycline antibiotic) induced cytoprotective autophagy
in MM cell lines and its combined use with chloroquine was found to synergistically impair the
tumour growth in a xenograft model of MM [214]. Elaiophylin, a macrolide antibiotic extracted
from Streptomycin melanosporus, is a potent autophagy inhibitor [215]. In p53 mutant MM cells,
Elaiphylin demonstrated an anti-myeloma activity in vitro and in vivo. Furthermore, Metformin
targets GRP78 (glucose-regulated protein 78)-dependent autophagy in MM cells and potentiate the
effect of Bortezomib on tumour regression with a significant survival benefit [216]. Carfilzomib is
a second-generation proteasome inhibitor that shows a significant decrease in cell viability when
combined with Chloroquine [217]. Furthermore, Chloroquine treatment can overcome the carfilzomib
resistance in vitro [218]. In this context of resistance to proteasome inhibitors, Lu et al. found that
Profilin1 (PFN1, a cytoskeleton protein) could bind to the BECN1 complex, to promote autophagy
and to induce Bortezomib resistance in MM [219]. Zhang et al. found that ClC5, a member of the
chloride channel family, promoted survival autophagy and chemoresistance in Bortezomib-treated
MM cells [220]. In another study, the chemoresistance to Mephalan was found to be associated with an
increased autophagy in MM cells. Mechanistically, the authors described that the high expression of
the long non-coding RNA Linc00515 and the subsequent direct inhibition of miR-140-5p resulted in
the upregulation of ATG14 levels and autophagy activation [221].
The work of Milan et al. identified SQSMT1/p62 as a novel specific anti-myeloma target,
conferring resistance to Bortezomib [222]. Indeed, the authors found that proteasome inhibition
not only induced increased SQSMT1/p62 expression levels but also facilitated its interaction with
ubiquitinated proteins for subsequent autophagic degradation. Therefore, the lentiviral-mediated
depletion in SQSMT1/p62 was found to increase cell sensitivity to proteasome inhibition. The authors
concluded that the detection of SQSMT1/p62 aggregates at diagnosis could represent a major
prognostic factor for MM patient’s intrinsic susceptibility to proteasome inhibitors.
In plasma cells physiopathology, Lamy et al. proposed recently that autophagy might play an
ambivalent role, that is, switching from cytoprotective or cytotoxic functions depending on caspase-10
activity. The authors found that caspase-10 inactivation (using Q-AEVD-OPH or shRNA targeting
caspase-10) led to the stabilization of the BCLAF1/BCL-2 complex and the unleashed activation
of BECN1, responsible for the autophagy process over-activation, culminating in autophagic cell
death [140]. Indeed, the molecular inhibition of BECN1 and ATG5, through targeted siRNA, protected
the cells against the autophagic cell death induced by caspase-10 inhibition.
Similarly, the work of Ma et al. pointed out the efficiency of combined chemotherapy
(Dexamethasome) and proteasome inhibition (PS-341/Bortezomib) in multiple myeloma cell lines [129].
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In this setting, one can hypothesize that survival autophagy was activated following proteasome
inhibition, as an alternative way to deal with misfolded protein aggregates and that the combination
with dexamethasone, by pushing toward excessive autophagy, induced a switch from cytoprotective
to cytotoxic autophagy. In 2008, another molecule, called compound A (CpdA), was described by
Chen et al. to stabilize p27 and induce caspase-independent cell death by activation of autophagy.
Importantly, this drug overcome resistance to chemotherapy as well as to proteasome inhibitor in MM
models, again strongly suggesting that killing of cells occurred through excessive CpdA-mediated
autophagy activation [223]. Recently, Betulinic acid (BetA) was found to induce either apoptosis or
autophagic cell death in MM cells, depending on the protein phosphatase 2A (PP2A) partner. Indeed,
the authors found that under normal conditions, BetA induces caspase-3 activation, cleavage of PP2A,
inactivation of Akt and subsequent apoptosis. However, under conditions where apoptosis was
blocked, the authors found that PP2A interacts with DAPK to induce autophagic cell death in BetA
treated cells [141]. Another study reported that the activation of the endoplasmic reticulum stress,
by using the drug Tunicamycin, induced autophagy and apoptosis in MM cells, thereby inhibiting
proliferation and chemotherapy resistance [224].
Altogether, these numerous studies highlight autophagy as a promising therapeutic target in
MM [225,226].
Primary Effusion Lymphoma (PEL): In 2011, Sommermann et al. described that the treatment of
B-NHL cells (including PEL but also DLBCL and lymphoblastoid cell lines) with chemical an NF-κB
inhibitor induced cytoprotective autophagy to overcome the GLUT1 transporter sequestration into the
cytoplasm and subsequent leading to a defect in glucose uptake and availability. The authors found
indeed that the combination of NF-κB inhibitors with the pharmacological inhibition of autophagy,
using Chloroquine and 3-Methyladenine, drove lymphoma cells to metabolic crisis and cell death [227].
In line with these data, Granato et al. reported that autophagy activity in PEL cells is mainly
pro-survival and inhibits anti-proliferative effects of proteasome inhibitors [228]. More recently,
the same group demonstrated that Quercetin, a flavonoid described as a PI3K/AKT/mTOR and STAT3
inhibitor, induces apoptosis and autophagy in PEL cells. Its combination with autophagy inhibitor
(Bafilomycin A or siBECN1) was found to improve cell death in these tumour cells [229].
Anaplastic Large Cell Lymphoma (ALCL), ALK (Anaplastic Lymphoma Kinase) positive: Regarding
the role of autophagy in ALK+ALCL therapy, Mitou et al. demonstrated that Crizotinib (the first
ALK tyrosine kinase inhibitor (TKI)) treatment induced cytoprotective autophagy and that combining
ALK inhibition with autophagy pharmacological or molecular inhibition improved the TKI drug
efficiency [158]. In a follow-up study, Torossian et al. further found that combining ALK inactivation
and BCL-2 molecular depletion resulted in the potentiation of autophagy and increased cell death
(Torossian et al., manuscript in press [230]).
Follicular lymphoma (FL): Understanding the role of autophagy in FL therapies is at its premise.
So far, the work of Brem et al. described that autophagy could be activated as an alternative cell
death program upon BH3-mimetic treatment (Obatoclax) in Rituximab (RTX)-resistant cell lines [231].
Similarly, Leseux et al. demonstrated in 2008 that RTX induced mTOR inactivation in FL cells and
further showed that the combination of RTX with rapamycin increased the anti-leukemic effect of the
drugs, strongly suggesting that enhanced autophagy may trigger FL cell death [232].
3.2.2. Acute Lymphoid Leukaemia
In various haematological cell lines (including ALL, CLL and multiple myeloma cell lines), Laane
et al. demonstrated in 2009 [233,234] that Dexamethasone treatment (a member of the glucocorticoide
(GC) class of hormones) induced autophagy first (as evidenced by LC3 turnover assay and puncta
formation), which was mandatory for the subsequent cell death by apoptosis. Indeed, autophagy
inhibition through siRNA targeting BECN1 or through type III phosphatidylinositol 3-kinase (PI3KIII)
complex chemical inhibition (using LY294002 and 3-Methyladenine) led to the inhibition of apoptosis.
Along the same line, Polak et al. recently showed that the MEK inhibitor Selumetinib enhanced
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Dexamethasone toxicity in GC-resistant B-ALL cells through the stimulation of autophagy [235].
Different compounds have been found to induce autophagic cell death in B- and T-ALL. This is the
case for Idarubicin (a chemotherapeutic drug (anthracycline)) [236] and for the mTORC1 inhibitor
(Everolimus), both of which were found to induce cytotoxic autophagy [237], through the enhanced
expression of BECN1 [238].
Back in 1997, Jia et al. first reported that TNFα-mediated apoptosis in T-ALL was abrogated upon
autophagy inhibition, pointing to an interplay between the two cell death process [239]. The treatment
of ALL cell lines with APO866 (an inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), a
key enzyme in nicotinamide adenine dinucleotide (NAD) biosynthesis) was found to induce autophagy
as a prerequisite for apoptotic cell death [194]. In line with these findings, Jiang et al. demonstrated
recently that autophagy inhibition decreased the apoptotic rate of T-ALL Jurkat cells submitted to
selenite treatment [240]. Two other studies demonstrated that glucocorticoide (GC)-induced apoptotic
cell death involved the initial activation of autophagy. Of note, resistance to GC occurs in 10% of
GC-treated B-ALL [241] and mainly involves a deficiency in apoptosis. Thus, treatment with the
BCL-2 inhibitor Obatoclax resulted in the resensitization to drug-induced apoptosis and was found
to trigger autophagic cell death [242]. Indeed, further studies showed that Obatoclax was able to
activate three types of cell death, that is, apoptosis, autophagy and necroptosis in infant ALL [243].
In this context, Bonapace et al. found that autophagy-dependent necroptosis allowed to overcome
GC resistance in T-ALL [244]. Finally, a recent gene expression profiling study in GC sensitive and
resistant paediatric patients with B-ALL revealed that an altered expression of autophagy-related
genes (converging towards autophagy inhibition) might contribute to the resistance phenotype [245].
As in other diseases, autophagy can also promote survival upon therapy. The work of
Wallington-Beddoe et al. demonstrated in 2011 that the immunosuppressive FTY720 compound
induced a caspase-independent cell death and a concomitant cytoprotective autophagy in B-ALL
cells [246]. This synthetic sphingosine analogue has been described as an autophagy inhibitor in
mantle cell lymphoma, highlighting the fact that drugs might have diverse effects on different
cells [190]. The Akt inhibitor Triciribine was found to induce cytoprotective autophagy since
Chloroquine co-treatment increased its cytotoxic effects [247]. More recently, the impairment of
NOTCH1-controlled glutaminolysis (through the inhibition of NOTCH1), combined with the inhibition
of the activated cytoprotective autophagy was found to have a synergistic anti-leukemic effect in
T-ALL [248]. L-asparaginase (L-asp) is one of the mostly used drug for childhood ALL therapy. Poor
response to this therapy has been linked to increased risk of relapse and therapy failures [249,250].
L-asp induces mitochondrial injury together with a cytoprotective autophagy to remove damaged
mitochondria. Inhibiting autophagy with Chloroquine improve the treatment responses both in vitro
and in vivo under these conditions [251].
4. Autophagy and Myeloid Tumours
4.1. Aberrant Autophagy in Myeloid Dysplastic Syndromes and Myeloid Leukaemia
4.1.1. Myelodysplastic Syndrome (MDS)
Myelodysplasic Syndrome (MDS) defines a heterogeneous group of hematopoietic diseases [252],
divided in five main subgroups in 1982 that is, Refractory Anaemia (RA), Refractory Anaemia with
Ring Sideroblasts (RARS), Refractory Anaemia with Excess of Blasts (RAEB), RAEB in transformation
(RAEB-t) and Chronic Myelomonocytic Leukaemia (CMML). These pathologies are characterized
by bone marrow cells morphology and abnormal cell numbers, peripheral blood cytopenias and
propensity for Acute Myeloid Leukaemia (AML) progression in one third of the cases. MDS are
clonal diseases, originated from hematopoietic stem cells [253,254], which acquired and accumulated
diverse genetic alterations, mainly the chromosomal deletion (del(5q)) and mutations in genes affecting
epigenetic control, transcription, RNA splicing or signal transduction pathways [255]. MDS occurs
predominantly in the elderly and can be cured by allogeneic hematopoietic cell transplantation
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(AHCT) [256]. However, only few patients could benefit from this therapeutic strategy because of their
advanced age and because of significant comorbidities and mortality associated with this procedure.
According to the type of MDS and to the risk stratification, different therapies have emerged during
the last two decades. It includes Erythropoiesis-Stimulating Agents (ESA), Hypomethylating Agents
(HMA) such as Azanucleosides, Lenalidomide, Immunosuppressive Therapy (IT) or Iron Chelation
Therapy (ICT) [257]. In this framework, several recent studies and one clinical trial highlight the
potential of autophagy modulation in the treatment of MDS.
Several studies tried to decipher the role of autophagy in MDS development. Interestingly,
increased expression of ATG2B and GSKIP due to germline copy number variation, predispose to
several myeloid malignancies such as myeloproliferative neoplasm [258]. On the other hand, Park et
al. demonstrated that MDS patients harbouring the mutation U2AF35(S35F) have increased ATG7
pre-mRNA levels that undergo aberrant distal cleavage at polyadenylation site [259]. This results
in a decreased of both, ATG7 expression and autophagic activity sensitizing cells to transformation.
In line with this data, nucleated red blood cells of high-risk MDS patients have lower LC3B levels
and more defective mitochondria. Furthermore, LC3B levels correlated with haemoglobin levels [260].
In addition, ATG3 is expressed at lower level in MDS patients compared to healthy individuals.
Furthermore overexpression of ATG3, in the SKM-1 MDS cell line induces an increase of autophagy
activity and a caspase dependent cell death at steady state [261].
4.1.2. Acute Myeloid Leukaemia
Acute Myeloid Leukaemia (AML) is the most common type (80%) of leukaemia in adults and mainly
occurs in the elderly. AML is characterized by an arrest in myeloid differentiation and an aberrant
cell survival/proliferation of leukaemia blasts with high clinical heterogeneity between individuals.
The heterogeneity of this disease renders the treatment a real challenge in the clinic [262] with the
exception of acute promyeloicytic leukaemia (APL) harbouring the chromosomal translocation t(15;17)
encoding for the oncogenic fusion protein PML-RARA. Although the World Health Organization
recently published a new and more precise classification of AML subtypes [263], very little progress
has been made in terms of treatment. According to the Swiss national institute for cancer epidemiology
research, the relative cumulative five year survival after AML diagnosis improved modestly between
2001–2007 and 2008–2013 from 19.2% to 23.3% in Switzerland [264]. The median age of AML patients
is about 70 years [265] and with the increasing number of elderly people in wealthy countries, the
prevalence of AML is expected to increase. Therefore, improvements in therapy are urgently needed.
A body of evidence indicates that primary AML blasts show low autophagy gene levels compared
to nonleukemic or differentiation undergoing AML cells [266,267]. In the same vein, the autophagy
receptor SQSMT1/p62 was shown to be upregulated during the neutrophil differentiation in APL cells.
Accordingly, it was reported that miR-17, -20, -93 and -106, which target SQSMT1/p62, are expressed
at higher levels in mouse and human hematopoietic blast cells than in neutrophils [268]. It is assumed
that the upregulation of SQSMT1/p62 prevents the accumulation of ubiquitinated protein aggregates
during terminal differentiation of APL cells and operates, as a pro-survival cellular mechanism in
this context [269,270]. Recent evidence also demonstrated that the SQSMT1/p62 is essential for cell
growth and the maintenance of mitochondrial integrity of murine myeloid leukaemia. Indeed, loss of
SQSMT1/p62 has been shown to impair leukaemia development and mitophagy in this leukaemia
type [271].
Several publications support the idea that the role of autophagy in leukaemia development
varies depending on the oncogene that can affect the progression in the disease. The RET
proto-oncogene is a receptor tyrosine kinase identified recently as an essential kinase in AML
development [272]. Interestingly, RET activated pathways lead to a reduction of autophagy
and stabilization of leukemogenic drivers such as mutant FLT3. Furthermore, inhibition of RET
leads to FLT3 depletion via autophagy. Interestingly, proteasome inhibitors promote FLT3-ITD
degradation through autophagy [273]. Conversely, inhibition of FLT3-ITD mutant in AML cells
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impairs autophagy-dependent proliferation in vitro and in vivo, indicating that FLT3-ITD supports a
high level of basal autophagy. This FLT3-ITD dependent autophagy relies on the ATF4 transcription
factor expression [274]. In AML cells with mutant NPM1, PML is stabilized within the cytoplasm. PML
cytoplasmic localization leads to phosphorylation of AKT that subsequently activates a pro-survival
autophagy [275].
In a MLL-ENL mouse model, inhibition of autophagy via knockout of Atg7 resulted in a modest
increase of leukaemia survival free of mice together with a decrease in leukaemia initiating cells
(LICs). MLL-ENL Atg7−/− LICs demonstrated an increased ROS production, linked to an increase
in mitochondria activity and cell death. Accordingly, MLL-ENL Atg7−/− blasts in the peripheral
blood are decreased due to enhanced apoptosis [276]. Surprisingly, Watson et al. demonstrated that
in MLL-ENL autophagy inhibition by either knocking out ATG7 or ATG5 leads to more aggressive
leukaemia in vivo. Furthermore, they demonstrated that MLL-ENL cells with decreased autophagy
activity allow for abnormal mitochondria activity, proliferation and a glycolytic shift [267]. In an
AML1-ETO AML mouse model, autophagy inhibits self-renewal potential of LICs [277].
Mll-Af9 (MA9) AML cells show high autophagic flux compared to normal bone marrow but
interestingly disruption of either Rb1cc1 or Atg5 does not affect growth or survival of MA9-AML cells
in both in vitro and in vivo [278]. Indeed, Liu et al. demonstrated that autophagy activity is needed for
the development of the disease but is dispensable for the maintenance of leukaemia in this particular
subtype [279].
The H2.0-like homeobox transcription factor (HLX), which is overexpressed in AML is
another factor involved in regulating hematopoietic differentiation. It has been reported that HLX
upregulation resulted in AMPK activation and increased viability of AML cells possibly via autophagy
activation [280].
Together, AML is a highly heterogeneous disease and therefore it is not surprising that autophagy
act as either a tumour promotion or suppression mechanism depending on the AML subtype.
4.1.3. Chronic Myeloid Leukaemia
Chronic myeloid leukaemia (CML) represents 15% of all leukaemias and mainly occurs in adults
(median age at diagnosis: 66). CML is characterized by the translocation t(9;22)(q34;q11) resulting
in the expression of the BCR-ABL fusion protein, which harbours an unrestrained tyrosine kinase
activity. It presents first as an indolent disease, also called the chronic phase (CP), which can last for
many years and corresponds to the expansion of myeloid cell progenitors from leukemic stem cells.
The loss of terminal differentiation leads to a more aggressive advanced phase (AP), characterized
by the accumulation of either myeloid blasts, pre-B lymphoma blasts or T cells blasts in 65%, 35%
and 5% of the cases, respectively. This evolution to “blast crisis” happens through the acquisition of
additional chromosomal abnormalities including p53 mutations. How BCR-ABL expression leads
to leukemogenesis has been widely investigated and many signalling pathways downstream of the
oncogenic tyrosine kinase have been found to be dysregulated. Since 2001, the standard front line
therapy for patients with newly diagnosed CML is ABL tyrosine kinase inhibitor (Imatinib) treatment.
The remarkable success of Imatinib treatment subsequently led to the new area of “targeted therapy”
for many other cancer types with a well-defined molecular abnormality. This treatment efficiently
controls disease progression unless mutations in the BCR-ABL oncogene (in 40% of the cases) or other
resistance mechanisms, for example, BCR-ABL amplification or increased drug efflux, occur. These
resistances occur in 15% of the patients within the first 5 years of the treatment and patients are either
treated by second generation TKI or by allogenic hematopoietic cell transplantation. For patients
who evolved towards a blast crisis, the prognosis remains poor. Thus, while the current ITK therapy
successfully allows to control CML progression for the majority of the patients (85%), future therapeutic
strategies are currently investigated to eradicate the disease, notably by targeting the leukemic stem
cells, which are known to be insensitive to the TKI treatment [281]. In this framework, the role of
autophagy has been found controversial, according to the drug treatment and to the downstream
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activated signalling pathway. Of note, an autophagy-mediated degradation of the fusion BCR-ABL
oncoprotein has also been reported, thus highlighting that a threshold of autophagy induction along
with BCR-ABL expression levels might control leukemic cell fate upon treatment [282].
It has been further demonstrated that BCR-ABL1 induces autophagy in a MAPK15-dependent
manner which potentially leads to cell transformation [283]. On the other hand Sheng et al. described
that BCR-ABL inhibits autophagy in a ATF5-dependent manner but only in transformed cells [284].
Interestingly, Lys05, a second generation of autophagy inhibitor, was shown to reduce CML
leukaemia stem cell quiescence and to induce maturation of CML cells [285]. Moreover, Lys05 or
PIK-III (an inhibitor of the PtIns3P class III) when combined with Tyrosine kinase inhibitor selectively
reduced the number of primary CML LSCs suggesting the relevance of this drug combination strategy
for killing cancer stem cells in CML patients [285].
Using a culture strategy by keeping cells first at low oxygen concentrations followed by
non-restricted O2 supply, Ianniciello et al. demonstrated that K562 CML cells or primary CML CD34+
cells needed autophagy for commitment but not for proliferation [286]. Furthermore, BIM1 expression
was proposed to support the progression of CML towards acute phases. Indeed, BIM1 inhibition
triggers CCNG2 expression and a drop in clonogenicity linked to a decrease in tumour-suppressive
autophagy response [287].
4.2. Autophagy-Based Treatment Strategies in Myeloid Dysplastic Syndromes and Myeloid Leukaemia
4.2.1. Myelodysplastic Syndrome (MDS)
A study performed on SKM1 myeloid cells has shown that their resistance to 5-Azacytidine
treatment could be circumvented through autophagy activation [288]. Of note, these results account
for the basis of a clinical trial using autophagy activators in the treatment of high risk MDS and AML
(Clinical trial number: NCT 01210274, Table 1). Accordingly, another recent study performed by the
same group on primary CMML myeloid cells, demonstrated that autophagy activation, through the
stimulation of the purinergic receptor P2RY6 and its downstream CAMKK2-PRKAA1-ULK1 signalling
pathway, was mandatory to restore the normal differentiation of monocytes to macrophages and
thus, could represent a new promising therapy for this pathology [81]. Interestingly, in SKM-1 MDS
cells, FOXO3A has been described as a positive regulator of autophagy. Silencing FOXO3A leads
to a reduction of autophagy and promotes differentiation induced by decitabine [289]. Dubois et
al. reported recently that LAMP2 deficiency (and subsequent major defects in Chaperone Mediated
Autophagy (CMA)) in Azacytidine-resistant MDS cells resulted in their hypersensitivity to lysosomes
and (macro)autophagy inhibitors. Thus, targeting macroautophagy in CMA deficient LAMP2low
MDS/AML patients appears as a new therapeutic option [290].
Autophagy precedes apoptotic cell death in CD34+ cells isolated from high-risk MDS and in MDS
cell lines following nutrient deprivation and inhibition of the NF-κB-activating IK-κB kinase complex
using the BAY11-7082 compound. In this framework, it has been shown that a bioenergic failure
drives the activation of autophagy and then apoptosis, as assessed by classical and typical cellular
features. However, the authors found that cell death occurred even in the context of autophagy or
apoptosis blockade, thus highlighting the high plasticity of MDS cells in their cell death modalities [291].
Bortezomib (Velcade) is a proteasome inhibitor widely used to treat cancers including MDS and AML.
Interestingly, Fang et al. demonstrated that Bortezomib induced degradation of TRAF6 via autophagy
leading to cell death while inhibiting autophagy using 3-Methyladenine leads to increased survival of
MDS and AML cells [292].
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Table 1. List of clinical trial involving autophagy modulation in hematopoietic cancers.
Haematological Malignancies Therapeutic Modulation of Autophagy Single Drug
or Combination
Clinical Trials
Number Phase
Chronic lymphocytic leukaemia
A
ut
op
ha
gy
In
hi
bi
ti
on Hydroxychloroquine (HCQ) NCT00771056 II
Multiple myeloma HCQ + Bortezomib NCT00568880 I/II
HCQ + Cyclophosphamide +
Dexamethasone + Rapamycin NCT01689987 I
Lymphoma Vinblastine NCT00059839 III
Chronic myeloid leukaemia HCQ + Imatinib NCT01227135 II
Acute myelogenous leukaemia HCQ + Mitoxantone + Etoposide NCT02631252 I
Chronic myeloid leukaemia
A
ut
op
ha
gy
In
du
ct
io
n
Everolimus (RAD001, mTORC1 inhibitor) NCT01188889 I/II
Chronic lymphocytic leukaemia
Everolimus + Alemtuzumab NCT00935792 I/II
CAL-101 (PI3Kd inhibitor) NCT01539512 III
Perfosine NCT00873457 II
Relapsed follicular or mantle cell lymphoma Temsirolimus (mTORC1 inhibitor) NCT01078142 I
Multiple myeloma Everolimus + Panobinostat(HDAC inhibitor) NCT00918333 I/II
Multiple myeloma, Lymphoma Everolimus + Sorafenib(multikinase inhibitor) NCT00474929 I/II
Acute monoblastic leukaemia Lithium NCT01820624 I
Advanced haematological malignancies Triciribine NCT00642031 I
Myelodysplasic syndrome and Autophagy inducer + Azacitidine NCT01210274 Recruiting
Acute myelogenous leukaemia
Relapsed/Refractory NHL or HL CAL-101
NCT01306643/NCT01393106
I/II
NCT01282424
Relapsed/Refractory NHL CAL-101 + Rituximab +/− Bendamustine
NCT01088048/NCT01732913
I
NCT01732926
CAL-101 + GS-9973 (Syk inhibitor) NCT01796470 II
Lymphoma malignancies IPI-145 (PI3Kd and PI3Kg inhibitor) NCT01476657 I
CC-223 (dual mTORC1 and
mTORC2 inhibitor) NCT01177397 I/II
Relapsed/Refractory/Newly
diagnosed lymphoma
Everolimus in combination therapies (+/−
Antibodies +/− TKIs +/− Chemotherapy)
NCT00869999/NCT01334502
I/II
NCT01198665/NCT01665768
NCT01854606/NCT01341834
NCT01075321/NCT01567475
NCT00352443/NCT01453504
Relapsed/Refractory lymphoma
Everolimus NCT00436618 II
Everolimus + Panobinostat NCT00962507/NCT00978432 I/II
Ridaforolimus (mTORC1 inhibitor) NCT00060632/NCT00060645NCT00086125 I/II
Ridaforolimus + Vorinostat
(HDAC inhibitor) NCT 01169532 I/II
4.2.2. Acute Myeloid Leukaemia
Standard treatment is based on chemotherapy, which successfully reduces the bulk of leukemic
cells but unfortunately spares the malignant stem or progenitor cells, therefore leading to a high
propensity for leukaemia relapses. Many studies have shown the induction of autophagy in AML
cells exposed to a variety of new drugs. In accordance with the known dual role of autophagy upon
anti-cancer therapies in solid tumours, both pro-survival and pro-death functions have been attributed
to autophagy in therapeutically challenged AML [293]. Furthermore, in a few studies activation of
autophagy primed AML cells towards other forms of cell death [291]. Finally, a switch from cytotoxic
to cytoprotective autophagy has been shown to occur in the same AML cell line, depending on the
concentration of AZD8055, a specific mTOR kinase inhibitor [294].
Conventional treatment of AML cells with chemotherapy can induce cytoprotective
autophagy through HMGB1 release. Indeed, the use of neutralizing antibodies potentiated the
chemotherapy-induced cytotoxicity [295]. Autophagy serves a critical role in protecting AML cells
from Cytarabine and in the development of Cytarabine resistance [296]. Targeting autophagy permits
to overcome Cytarabine resistance not only in AML cells but also in co-culture of AML cells with
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marrow-derived mesenchymal stromal cells [297]. Furthermore, Cytarabine treatment induces
autophagy in leukaemia-initiating cell and autophagy inhibition sensitizes cells to the anti-leukemic
effect of Cytarabine supporting again to the contribution of autophagy to Cytarabine resistance [276].
However, low dose of Cytarabine treatment promotes cytotoxic autophagy in U937 AML cells
highlighting that the effect of autophagy on cell demise depends at least in part on the dose of
anti-cancer therapy used [298].
Several groups have demonstrated that pro-survival autophagy is activated in AML cells
submitted to dual mTORC1/mTORC2 inhibitors [294,299]. Along the same line, it was found that
inhibition of mTORC1, following L-asparaginase treatment in AML cells, resulted in cytoprotective
autophagy [300].
Simonsen et al. also demonstrated that treatment with HDAC inhibitors induced cytoprotective
autophagy in AML1-ETO-positive AML cells, at least in part through mTOR inactivation. Furthermore,
the authors showed that inhibition of autophagy by either the concomitant use of 3-Methyadenine
or Chloroquine or the molecular down-regulation of ATG7 resulted in increased apoptosis [301].
In the same vein, potent repression of autophagy through ATG7 downregulation was associated
with mitochondrial homeostasis defects, ROS accumulation, DNA damage and apoptotic cell death
in a specific subset of AML cells (Down syndrome) submitted to HDACi, further highlighting the
cytoprotective function of autophagy in this context [302].
The combination of Obatoclax, an inhibitor of the anti-apoptotic proteins BCL-2, BCL-xL and Mcl-1
with Sorafenib (a multi-kinase inhibitor) was also shown to induce cytoprotective autophagy in AML
cells. Indeed, the pharmacological inhibition of autophagy by using 3-Methyladenine, Chloroquine or
Bafilomycin A1, strongly potentiated cell toxicity of the drug combination [303].
Early studies tended to associate the accumulation of autophagosomes in AML cells to the
occurrence of cell death. This was the case in the HL60 AML cell line submitted to Morphinone [304]
and to AML cells and primary cells from patients submitted to APO866 (a NAD biosynthesis
inhibitor) [194,195]. More recently, Ristic et al. demonstrated the activation of an mTOR-dependent
cytotoxic autophagy upon Idarubicin treatment [236]. Interestingly, the AMPK agonist GSK621 has
been shown to promote autophagy concomitantly to mTOR activation, a process that leads to AML
cell killing [305]. Arsenic trioxide treatment of AML cells was also shown to elicit autophagy cell death
through a mechanism that is not fully understood [306].
In addition, autophagy is involved in the degradation of certain AML oncoproteins such
as PML-RARA and FLT3-ITD [273,307] but not AML1-ETO [301]. These results demonstrate
that autophagy can selectivity eliminate oncoproteins through mechanisms that warrant further
investigation. All-trans retinoic acid (ATRA), a potent differentiation agent, has been reported to
effectively promote clinical remission of APL when combined with anthracyclines or arsenic trioxide
(ATO) [308]. Importantly, several groups showed activation of autophagy during ATRA-induced
granulocytic differentiation of APL cells [307,309–312]. This response occurs through WIPI dependent
and BECN1 independent mechanism and is associated with increased expression of GATE16, MAP1S,
DRAM1, HMGB1 and SQSMT1/p62 [269,310,312–316]. ATRA treatment also induced selective
degradation of ubiquitinated proteins through a SQSMT1/p62 dependent mechanism [269]. While
molecular and pharmacological inhibition of autophagy attenuated granulocytic differentiation of
APL cells, downregulation of BECN1 and SQSMT1/p62 expressions did not affect this process but
rather promoted APL cell death. Autophagy was assumed to promote differentiation of APL cells
through a mechanism that relies on PML-RARA degradation. Interestingly, recent studies have
revealed that non-coding RNAs, that is, the microRNA (miR) miR125B1 and the long noncoding RNA
(lncRNA) HOTAIRM1 could negatively or positively regulate the degradation of PML-RARA during
the process of ATRA-mediated myeloid cell differentiation, respectively [317,318]. PML-RARA is
also cleared upon arsenic trioxide treatment of APL through a mechanism that involves proteasomal
and autophagic pathways [319]. The combination of ATRA with Dasatinib also promoted autophagy
and the differentiation of leukemic cells [320]. Finally, Goussetis et al. demonstrated that APO
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treatment of non-APL cells resulted in autophagic cell death through the activation of the MEK/ERK
pathway [306]. However, another study has shown that APO inhibited the autophagic flux [321].
Altogether, these studies point to the distinct roles of several autophagy-regulatory pathways in acute
myeloid leukaemia cells demise.
4.3. Chronic Myeloid Leukaemia
Goussetis et al. first reported the autophagic degradation of the BCR-ABL oncoprotein in CML
cells under arsenic trioxide (ATO) treatment in 2012 [282]. Elzinga et al. further confirmed that Imatinib
treatment induced also the sequestration of the BCR-ABL oncoprotein in autophagosomes, allowing
its subsequent degradation [322]. These results are important since they highlight for the first time
that autophagy intensity and/or duration, within a drug treated leukemic cells, could control its fate,
from survival to cell death, through the tight regulation of the driven oncogene expression levels.
Carew et al. reported that the treatment of different CML cell lines and primary CML cells
expressing wild-type and Imatinib-resistant mutant forms of BCR-ABL, including T315I, with an
histone deacetylase inhibitor (suberoylanilide hydroxamic acid (SAHA)) induced autophagy and that
its inhibition (by using Chloroquine) potentiated the anti-neoplastic effects of SAHA [323]. Two years
later, Bellodi et al. reported a study of noticeable clinical importance which showed that Imatinib
treatment of CML cells induced cytoprotective autophagy and that the inhibition of autophagy, by
using pharmacological (Chloroquine, Bafilomycin A1) or RNA interference of essential autophagy
genes (ATG5, ATG7) potentiated the drug efficiency not only in CML blast crisis cell lines and CML
primary cells but also in leukemic stem cells isolated from patients [324–326]. In line with these findings,
Crowley et al. reported that pharmacological agents with inherent anti-autophagic activity improved
the cytotoxicity of imatinib [327]. More recently, Zeng et al. found a synergistic effect when combining
the inhibition of Hedgehog signalling, which is important for the malignant stem cell maintenance
and the inhibition of autophagy [328]. Compounds such as Resveratrol, a natural phytoalexin isolated
from grapes) and Acadesine (AICAR, 5-aminoimidazole-4-carboxyamide ribonucleoside, known to
activate AMPK) were found to induce autophagic cell death in both sensitive or resistant CML cell lines
to Imatinib, through AMPK activation and SQSMT1/p62 upregulation [329,330] and through PKC
activation [331], respectively. More recently, Tong et al. found that an oncolytic adenovirus expressing
BECN1 was efficient in inducing autophagic cell death in different leukemic cell lines and primary
leukemic blasts, along with Imatinib resistant cells [332].
5. Conclusions
While a lot of effort was put into understanding the role of autophagy in cell transformation and
the benefit of autophagy-based treatment strategies, the function of autophagy remains ambiguous in
hematopoietic cancers. Furthermore, in many settings autophagy has been shown to play a divergent
role in the outcome of hematopoietic cancers, thus, caution should be taken when the modulation of
autophagy is considered as a therapeutic strategy to improve the treatment of hematopoietic cancers.
Several points have been discussed already to try to solve issues encountered in many different
diseases where autophagy-based therapy might be an option [333]. Nevertheless, as shown in Table 1,
modulating autophagy in hematopoietic cancer is attractive and may open new avenues for efficient
treatment strategies.
In addition, autophagy can be either selective or non-selective and several examples highlight
non-canonical autophagy regulation in some hematopoietic cancers. Understanding how the
autophagy machinery is involved in healthy and malignant hematopoietic cells as well as identifying
the role of specific autophagic cargos during transformation, maintenance and treatment response will
help us to have better understanding the role of autophagy in haematopoiesis and to develop new
targeted strategies to improve treatment of hematopoietic diseases. Furthermore, recently a study on
Chloroquine demonstrated that unlike Bafilomycin A1, Chloroquine and Hydroxychloroquine leads to
an accumulation of autophagosomes [334]. Additionally, Chloroquine alters the Golgi organization and
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causes the vacuolization of lysosomes. Therefore, pre-clinical and clinical studies that used Chloroquine
as only autophagy inhibitor should be validated by using more specific autophagy modulators.
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